-
Something wrong with this record ?
Long-Term Immunological Alertness and Response to COVID-19 Vaccination-Conditions for Prevention in Early Palliative Oncological Care Patients
P. Priester, M. Fajfr, V. Molnarova, R. Sleha, S. Janovska, P. Bostik, S. Filip
Status not-indexed Language English Country Switzerland
Document type Journal Article
Grant support
NU20-09-00045
Agentura Pro Zdravotnický Výzkum České Republiky
NLK
Directory of Open Access Journals
from 2013
Free Medical Journals
from 2013
PubMed Central
from 2013
Europe PubMed Central
from 2013
ProQuest Central
from 2013-03-01
Open Access Digital Library
from 2013-01-01
Open Access Digital Library
from 2013-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2013
- Publication type
- Journal Article MeSH
Aside from the general population, the COVID-19 pandemic has also affected a group of patients in palliative oncology care. In this study, long-term immune responses against SARS-CoV-2 after vaccination were monitored in a cohort of patients in palliative oncology care. This non-randomized, prospective, and open-label pilot study recruited patients from the Palliative Oncology Program and included 147 patients, of which 80 were females (54.4%) and 67 males (45.6%). The overall evaluation included current health status, SARS-CoV-2 anti-S IgG titer, and neutralizing antibodies using the SARS-CoV-2 virus neutralization test (VNT). Anti-S IgG antibody analysis revealed high (H) antibody levels in 35.7% (n = 10) and very high (VH) levels in 39.3% (n = 11) of patients after the second vaccination dose. Similarly, after the third dose, H was found in 29.6% (n = 32) and VH in 55.5% (n = 60) of patients. High and very high anti-S IgG antibody levels were consistent with high VNT titers (>2560) and H antibody levels in 17.1% (n = 12) or VH in 82.9% (n = 58) of patients. Patients with two or more doses showed H and VH antibody levels at a median of 451 and 342 days after vaccination, respectively. In this clinical trial, patients showed high and very high levels of anti-S IgG antibodies over a longer period of time. These patients did not show reduced immunological responses to the COVID-19 vaccine challenge. We can assume that prevention through vaccination can reduce the risk of complications or death from COVID-19 in patients in early palliative oncology care.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24005597
- 003
- CZ-PrNML
- 005
- 20240412130935.0
- 007
- ta
- 008
- 240405s2024 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/vaccines12030299 $2 doi
- 035 __
- $a (PubMed)38543933
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Priester, Peter $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic
- 245 10
- $a Long-Term Immunological Alertness and Response to COVID-19 Vaccination-Conditions for Prevention in Early Palliative Oncological Care Patients / $c P. Priester, M. Fajfr, V. Molnarova, R. Sleha, S. Janovska, P. Bostik, S. Filip
- 520 9_
- $a Aside from the general population, the COVID-19 pandemic has also affected a group of patients in palliative oncology care. In this study, long-term immune responses against SARS-CoV-2 after vaccination were monitored in a cohort of patients in palliative oncology care. This non-randomized, prospective, and open-label pilot study recruited patients from the Palliative Oncology Program and included 147 patients, of which 80 were females (54.4%) and 67 males (45.6%). The overall evaluation included current health status, SARS-CoV-2 anti-S IgG titer, and neutralizing antibodies using the SARS-CoV-2 virus neutralization test (VNT). Anti-S IgG antibody analysis revealed high (H) antibody levels in 35.7% (n = 10) and very high (VH) levels in 39.3% (n = 11) of patients after the second vaccination dose. Similarly, after the third dose, H was found in 29.6% (n = 32) and VH in 55.5% (n = 60) of patients. High and very high anti-S IgG antibody levels were consistent with high VNT titers (>2560) and H antibody levels in 17.1% (n = 12) or VH in 82.9% (n = 58) of patients. Patients with two or more doses showed H and VH antibody levels at a median of 451 and 342 days after vaccination, respectively. In this clinical trial, patients showed high and very high levels of anti-S IgG antibodies over a longer period of time. These patients did not show reduced immunological responses to the COVID-19 vaccine challenge. We can assume that prevention through vaccination can reduce the risk of complications or death from COVID-19 in patients in early palliative oncology care.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Fajfr, Miroslav $u Institute of Clinical Microbiology, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic $u Institute of Clinical Microbiology, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000235619482 $7 xx0238808
- 700 1_
- $a Molnarova, Veronika $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Sleha, Radek $u Institute of Clinical Microbiology, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic $u Department of Epidemiology, Military Medical Faculty, University of Defense, 500 01 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000173599147
- 700 1_
- $a Janovska, Sylva $u Department of Epidemiology, Military Medical Faculty, University of Defense, 500 01 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000323848875 $7 xx0033210
- 700 1_
- $a Bostik, Pavel $u Institute of Clinical Microbiology, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic $u Institute of Clinical Microbiology, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000326916458
- 700 1_
- $a Filip, Stanislav $u Department of Oncology and Radiotherapy, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000285670745 $7 jn20010309153
- 773 0_
- $w MED00200686 $t Vaccines $x 2076-393X $g Roč. 12, č. 3 (2024)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38543933 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240405 $b ABA008
- 991 __
- $a 20240412130927 $b ABA008
- 999 __
- $a ok $b bmc $g 2075968 $s 1215359
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 12 $c 3 $e 20240313 $i 2076-393X $m Vaccines $n Vaccines (Basel) $x MED00200686
- GRA __
- $a NU20-09-00045 $p Agentura Pro Zdravotnický Výzkum České Republiky
- LZP __
- $a Pubmed-20240405
